# Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

> **NCT01991067** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 34 (actual)

## Conditions studied

- Tick Borne Encephalitis

## Interventions

- **BIOLOGICAL:** TBE virus vaccine

## Key facts

- **NCT ID:** NCT01991067
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2018-10-28
- **Final completion:** 2018-10-28
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01991067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01991067, "Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01991067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*